NYSE:ADCT ADC Therapeutics Q2 2026 Earnings Report $1.10 +0.06 (+5.24%) As of 02:35 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast ADC Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.19Beat/MissN/AOne Year Ago EPSN/AADC Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$18.89 millionBeat/MissN/AYoY Revenue GrowthN/AADC Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile ADC Therapeutics Earnings HeadlinesADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Hold" by AnalystsJuly 29, 2026 | americanbankingnews.comADC Therapeutics LtdJuly 9, 2026 | cnn.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.August 4 at 1:00 AM | Reagan Gold Group (Ad)Analysts Are Bullish on Top Healthcare Stocks: ADC Therapeutics (ADCT), Moleculin Biotech (MBRX)July 2, 2026 | theglobeandmail.comADC Therapeutics Announces New Employee Inducement GrantJuly 1, 2026 | prnewswire.comADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination TrialJune 30, 2026 | prnewswire.comSee More ADC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ADC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADC Therapeutics and other key companies, straight to your email. Email Address About ADC TherapeuticsADC Therapeutics (NYSE:ADCT) is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity. At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with relapsed or refractory large B-cell lymphoma. In addition to this approved asset, the company’s pipeline features multiple next-generation ADC candidates targeting novel antigens, several of which are advancing through late-stage clinical trials. Founded in 2012 as a spin-out from Heidelberg University, ADC Therapeutics is headquartered in Lausanne, Switzerland, with additional offices in London and New York. Its global footprint spans Europe and North America, encompassing clinical research sites and manufacturing partnerships that support multi-regional trials and scaled production of its specialized conjugates. The company is led by a management team with deep expertise in antibody engineering, oncology drug development and regulatory affairs. Through collaborations with academic institutions and industry partners, ADC Therapeutics seeks to accelerate its translational research efforts and bring innovative ADC therapies to patients battling blood cancers.View ADC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
